Halozyme Therapeutics Inc. (HALO) earns a Roarable Rating of B (Buy) with 75/100 RQD Confidence. High-quality cash engine (84% profit margin, 18% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
As of 2026-11-03, Halozyme Therapeutics Inc. (NASDAQ: HALO) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 75/100 at a spot price of $130.91 (-0.21% 1D, market cap $14.86B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, HALO ranks #32 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), HALO carries a Roarable B (75/100 RQD), trailing P/E of 47.0x, gross margin of 83.6%, and ROIC of 18.0%. By comparison, NBIX (Neurocrine Biosciences Inc.) holds a B grade (73/100 RQD, P/E 31.1x, ROIC 15.7%, cap $14.85B) and EXEL (Exelixis Inc.) posts a A grade (91/100 RQD, P/E 21.0x, ROIC 35.1%, cap $16.93B). Among the 5-stock peer group, EXEL leads on earnings multiple (21.0x) while EXEL leads on capital efficiency (35.1% ROIC).
Per HALO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001159036), Halozyme Therapeutics Inc. generated $1.40B in revenue (+37.6% YoY), $316.9M in net income, and $644.6M in free cash flow against $2.53B in total assets and $2.14B in total debt. Key quantitative strengths: Strong cash generator (84% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 47x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 46.2% FCF Margin ($644.6M FCF) & 83.6% Gross Margin
20D Institutional Volume Accumulation (±5.4% realized swing band)
Macro rate sensitivity & RSI-14 (77.8) create a -9 pt regime headwind
Even with a 75/100 (B) score, HALO faces multiple-compression risk if 47.0x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Priced at 47x earnings—high expectations leave less room for a lukewarm quarter.
Dilution & Margin Drag: Cannibal Buyback (-1.52% YoY Shares) — any gross margin slip below 81.1% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($115.05) or 200D SMA ($84.27) invalidates the momentum regime and cuts Target Base ($140.92) toward Bear Floor ($107.35).
Halozyme Therapeutics Inc. (HALO) slipped -0.21% to $130.91, trading at 96% of its 52-week range ($61.23 – $134). High-quality cash engine (84% profit margin, 18% return on capital) with steady institutional support.
Yahoo! Finance Canada report covering Halozyme Therapeutics Inc. (HALO) market action, institutional positioning, and fundamental catalysts.
ChartMill report covering Halozyme Therapeutics Inc. (HALO) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Halozyme Therapeutics Inc. (HALO) market action, institutional positioning, and fundamental catalysts.
Trefis report covering Halozyme Therapeutics Inc. (HALO) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Halozyme Therapeutics Inc. (HALO) market action, institutional positioning, and fundamental catalysts.
FXEmpire report covering Halozyme Therapeutics Inc. (HALO) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Halozyme Therapeutics Inc. (HALO) market action, institutional positioning, and fundamental catalysts.
ChartMill report covering Halozyme Therapeutics Inc. (HALO) market action, institutional positioning, and fundamental catalysts.
Is EXEL a good stock to buy? We came across a bullish thesis on Exelixis, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on EXEL. Exelixis, Inc.’s share was trading at $66.28 as of Oc
Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +37.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on HALO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for HALO. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Halozyme Therapeutics Inc. (HALO) ranks #32 by composite RQD confidence (75/100, grade B) and #80 by equity capitalization ($14.86B). Within this direct 5-issuer industry benchmark cohort, EXEL leads on earnings valuation at 21.0x trailing P/E, while EXEL leads on capital efficiency and profitability with 35.1% ROIC and 96.0% gross margin. EXEL currently holds the highest overall quantitative score in the immediate peer group at 91/100 (A) compared with HALO at 75/100 (B).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| HALO
ACTIVE
Halozyme Therapeutics Inc. | B | 75/100 | 47.0x | 83.6% | 18.0% | -0.21% | $14.86B | Benchmark Subject |
| NBIX Neurocrine Biosciences Inc. | B | 73/100 | 31.1x | 96.0% | 15.7% | -0.19% | $14.85B | /nbix-vs-halo → |
| EXEL Exelixis Inc. | A | 91/100 | 21.0x | 96.0% | 35.1% | +4.82% | $16.93B | /exel-vs-halo → |
| TECH Bio-Techne Corp | B | 72/100 | 155.3x | 64.8% | 3.4% | -0.07% | $11.39B | /tech-vs-halo → |
| KYMR Kymera Therapeutics Inc. | D | 51/100 | 32.7x | — | -21.4% | +3.29% | $10.81B | /kymr-vs-halo → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Halozyme Therapeutics Inc. (HALO) reported GAAP revenue of $1.40B (+37.6% vs. FY2024 revenue of $1.02B , and +68.4% cumulative change since FY2023) , GAAP net income of $316.9M, operating cash flow of $651.6M, and free cash flow of $644.6M (+37.6% YoY). On the balance sheet, HALO closed FY2025 with $2.53B in total assets against $2.14B in total debt (Altman Z-Score: 5.11, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.40B | $316.9M | $651.6M | $644.6M | $2.53B | $2.14B |
| FY2024 (FY) | 2024-12-31 | $1.02B | $444.1M | $479.1M | $468.4M | $2.06B | $1.51B |
| FY2023 (FY) | 2023-12-31 | $829.3M | $281.6M | $388.6M | $351.3M | $8.19B | $1.92B |
As of 2026-11-03, Halozyme Therapeutics Inc. (NASDAQ: HALO) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 75/100 at a spot price of $130.91 (-0.21% 1D, market cap $14.86B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, HALO ranks #32 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), HALO carries a Roarable B (75/100 RQD), trailing P/E of 47.0x, gross margin of 83.6%, and ROIC of 18.0%. By comparison, NBIX (Neurocrine Biosciences Inc.) holds a B grade (73/100 RQD, P/E 31.1x, ROIC 15.7%, cap $14.85B) and EXEL (Exelixis Inc.) posts a A grade (91/100 RQD, P/E 21.0x, ROIC 35.1%, cap $16.93B). Among the 5-stock peer group, EXEL leads on earnings multiple (21.0x) while EXEL leads on capital efficiency (35.1% ROIC).
Per HALO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001159036), Halozyme Therapeutics Inc. generated $1.40B in revenue (+37.6% YoY), $316.9M in net income, and $644.6M in free cash flow against $2.53B in total assets and $2.14B in total debt. Key quantitative strengths: Strong cash generator (84% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 47x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.
HALO last traded at $130.91 (-0.21% on volume of 1,402,663 shares), positioning the stock +13.79% above its 50-day simple moving average ($115.05) and +55.35% above its 200-day simple moving average ($84.27). Across its 52-week range of $61.23 to $134.00, HALO sits at the 95.8% percentile with a 14-day RSI of 77.8 (OVERBOUGHT (>70)) and an implied next-earnings move of ±5.4% ($123.84 to $137.98).
Why HALO Stock slipped -0.21% Today — RQD Quant Desk Flash. High-quality cash engine (84% profit margin, 18% return on capital) with steady institutional support.
Per the Roarable RQD rating, HALO scores 75 out of 100, a letter grade of B, labeled "Roarable Buy — Good Risk/Reward." The five pillars are:
Taken together, the rating points to quality operations and institutional support offset by valuation (P/E TTM of 47) and macro-fit weakness. Valuation tradeoffs are central: the stock trades at a premium multiple, so upside depends on sustained earnings growth.
Per the profile, Halozyme Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Biological Products (No Diagnostic Substances). Per the profile, its market capitalization is $14.9B. Not available in source data: product lines, customer base, and revenue mix. The source data does not describe how the company generates revenue beyond its sector and industry classification.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $1396.6M | $469.0M | $316.9M | N/A | $644.6M | $133.8M | $2142.6M |
| FY 2024 | $1015.3M | $551.5M | $444.1M | N/A | $468.4M | $115.8M | $1505.8M |
| FY 2023 | $829.3M | $337.6M | $281.6M | N/A | $351.3M | N/A | $1916.2M |
Per the SEC financials, revenue rose from $829.3M in FY 2023 to $1396.6M in FY 2025, while FCF rose from $351.3M to $644.6M. Per the market data, gross margin is 83.6%, operating margin 33.6%, and net margin 22.7%, with ROIC of 18%. Per the Roarable RQD rating, the Altman Z-Score is 5.11 and the Piotroski F-Score is 7/9, both supportive readings. Debt rose from $1916.2M (FY 2023) to $2142.6M (FY 2025), and the Debt/Equity of 8.5 per the RQD pillar data signals meaningful leverage. Net income declined from $444.1M in FY 2024 to $316.9M in FY 2025 even as revenue grew.
Per the recent news feed, six items reference HALO:
Per the Butterfly supply-chain graph, the supply chain is listed as "NONE," with no butterfly links and no proprietary signals. The catalyst picture is therefore headline-level only; the source data does not establish the earnings dates, magnitudes, or the content of the risk item.
Real-time company headlines, analyst actions, and sector developments for Halozyme Therapeutics Inc. (HALO) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Halozyme Therapeutics Inc. (HALO) market action, institutional positioning, and fundamental catalysts.
ChartMill report covering Halozyme Therapeutics Inc. (HALO) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Halozyme Therapeutics Inc. (HALO) market action, institutional positioning, and fundamental catalysts.
Trefis report covering Halozyme Therapeutics Inc. (HALO) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Halozyme Therapeutics Inc. (HALO) market action, institutional positioning, and fundamental catalysts.
FXEmpire report covering Halozyme Therapeutics Inc. (HALO) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Halozyme Therapeutics Inc. (HALO) market action, institutional positioning, and fundamental catalysts.
ChartMill report covering Halozyme Therapeutics Inc. (HALO) market action, institutional positioning, and fundamental catalysts.
Welcome to the HALO (Halozyme Therapeutics Inc.) Roar Pit. Current RQD Composite is 75/100 (Roarable Buy — Good Risk/Reward) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to capital efficiency (18.0% ROIC), while bears focus on valuation multiple compression (47.0x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on HALO, but look at what you are paying: 47.0x trailing P/E with 83.6% gross margins. Unless Halozyme Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on HALO, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $131.18 (52-wk range $61.23 - $134.00), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).